GNLX
Genelux Corporation
NASDAQ · Healthcare · Biotechnology · US
$2.44
−3.17%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 8.94x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.85x
- Price / sales
- —
- Price / cash flow
- -4.37x
Enterprise value
- Enterprise value
- $94.1M
- EV / sales
- —
- EV / EBITDA
- -2.75x
- EV / EBIT
- -2.64x
- Market cap
- $110.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026